People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.
Partly out of date: This report was assessed in July 2015 and some conclusions may not be current.
This is an evidence report prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center (EPC) concerning the benefits and harms associated with using angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), either alone or in combination, in people with stable ischemic heart disease or ischemic heart disease risk equivalents and intact left ventricular systolic function.
While the role of ACE inhibitors and ARBs in patients with post-myocardial infarction left ventricular dysfunction or chronic heart failure is well established, the role for these modalities in patients with stable ischemic heart disease or ischemic heart disease risk equivalents and preserved left ventricular systolic function is not as clear. The aim of this report is to acquire, assess, and summarize the current evidence about the benefits and harms associated with the use of ACE inhibitors and ARBs, either alone or in combination, in this patient population. The information is intended to inform clinicians, payors, and the public, while helping to define avenues for future research.
Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II–Receptor Blockers for Ischemic Heart Disease. Ann Intern Med. 2009;151:861-871. doi: 10.7326/0000605-200912150-00162